Skip to Main Content

Cassava Sciences (SAVA) CEO Remi Barbier is 13 days away from a $3 million cash bonus, thanks to a well-timed change in the company’s executive compensation plan and a questionable reanalysis of an unsuccessful Alzheimer’s disease drug clinical trial.

Barbier has a reputation for profiting personally even while his company suffered multiple setbacks. This latest money grab is particularly shameless because it’s practically risk-free — for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.